Professor Oliver Sartor is an internationally recognized expert in prostate cancer currently Medical Director at Tulane Cancer Center, United States. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 400 articles and book chapters and led multiple national and international clinical trials as either a principal investigator or co-principal investigator. In particular he has helped to lead pivotal trials leading to FDA approval for samarium-153 EDTMP, radium-223, and cabazitaxel.
He has published approximately 400 scientific articles and has given hundreds of invited lectures on advanced prostate cancer in 33 countries through the years.